E Fund Management Co. Ltd. reduced its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 45.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,829 shares of the company’s stock after selling 7,446 shares during the period. E Fund Management Co. Ltd.’s holdings in Dyne Therapeutics were worth $312,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC lifted its position in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the period. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the period. SG Americas Securities LLC acquired a new position in Dyne Therapeutics during the second quarter valued at $217,000. American Century Companies Inc. acquired a new position in Dyne Therapeutics during the second quarter valued at $228,000. Finally, EntryPoint Capital LLC acquired a new position in Dyne Therapeutics during the first quarter valued at $214,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Dyne Therapeutics
In related news, CEO John Cox bought 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Susanna Gatti High sold 29,787 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. Corporate insiders own 20.77% of the company’s stock.
Analyst Ratings Changes
Dyne Therapeutics Stock Down 0.8 %
DYN stock opened at $34.34 on Thursday. The stock has a market capitalization of $3.00 billion, a P/E ratio of -8.65 and a beta of 1.07. The firm has a 50-day simple moving average of $41.38 and a 200-day simple moving average of $33.47. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Dividend Payout Ratio Calculator
- How Much Can You Make in Stocks in One Month?
- How to Use the MarketBeat Stock Screener
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.